
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is poised for success in the biopharmaceutical industry with its innovative therapeutic platforms and promising pipeline, including zanidatamab, which has recently FDA approved for the treatment of gastroesophageal and other solid tumors that express HER2. In addition to this, Zymeworks' recent acquisition of Theravance brings in substantial royalty opportunities and strengthens its commercial capabilities. With a strong financial position and diverse pipeline, Zymeworks has the potential to be a top-performing stock.
Bears say
Zymeworks is a clinical-stage biopharmaceutical company that faces multiple risks including lower-than-expected revenues and higher-than-expected operating expenses. Despite positive developments in their pipeline, such as the upcoming HER2+ GEA PDUFA and potential approval milestones, the company's current cash balance and upcoming debt repayment may limit their ability to create shareholder value in the near term. Overall, the outlook for Zymeworks is negative due to these risks and limited potential for near-term financial success.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares